USUdo Schneider

Udo Schneider

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Udo Schneider has a total of 291 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding Health-related quality of life in rheumatologic diseases: insights from PROMIS® health domains

    by Milan Kock, Christoph Paul Klapproth, Annika Döhmen, Jonas Prenißl, Felix Fischer, Udo Schneider, Matthias Rose, Alexander Obbarius

    Background: Rheumatologic diseases significantly impact health-related quality of life (HRQoL), affecting physical, mental, and social well-being and pose unique challenges due to their wide range of symptoms. Patient-reported outcomes (PROs) provide valuable insights into how these diseases influence different dimensions of HRQoL, supporting personalized healthcare approaches. Methodology: In this cross-sectional study, we examined HRQoL in 213 patients with rheumatologic diseases, including, among others, rheumatoid arthritis, localized pain disorders, connective tissue diseases, and rarer conditions such as vasculitis, using the EQ5D-5L and the Patient-Reported Outcomes Measurement Information System (PROMIS ® ) as well as Pain and HRQoL specific PROs. We provided PROMIS health domain scores of key health aspects such as physical function, fatigue, pain interference, and social participation. Additionally, we compared HRQoL and PROMIS domain scores with a German general population reference sample and conducted exploratory comparisons across the three most frequent principal diagnosis groups: systemic sclerosis, rheumatoid arthritis, and vasculitis. Moreover, we investigated which patient-reported health domains were most strongly associated with HRQoL in these diseases. Penalized regression models with elastic net regularization were used to identify stable predictors of HRQoL, followed by a pooled linear regression model for interpretation. Results: Individuals with rheumatic diseases had significantly lower HRQoL than the general population (EQ-5D-5L VAS mean: 55.4 versus 73.2). PROMIS T-scores indicated markedly reduced Physical Function (M = 36.5, SD = 9.6) and elevated pain interference (M = 61.7, SD = 9.2). Penalized regression analyses identified Physical Function, Fatigue, Ability to Participate in Social Roles and Activities as stable predictors of EQ-5D-5L VAS. Higher Physical Function and Social Participation were associated with higher HRQoL, whereas higher Fatigue was associated with lower HRQoL. Conclusions: These results highlight the importance of PROs in understanding the patient experience in rheumatologic disease and identifying individual needs. Routine assessment of HRQoL domains may help recognize unmet needs and support individualized care in rheumatology.

  • Cytokine-mediated activation of kidney-infiltrating CD8 + T cells enables their contribution to inflammation in human lupus nephritis

    by Christopher M. Skopnik, Jan Klocke, Paul Freund, Diana Metzke, Lennard Ostendorf, Mario Bunse, Luka Prskalo, Johanna Kotzbauer, Christian Hinze, Emil Grothgar, et al.

    Proliferative lupus nephritis (LN) is triggered by deposition of autoantibodies in glomeruli and paralleled by a T cell–rich kidney infiltrate. Although these T cells have been attributed to the propagation of tissue injury, it is unclear how they are activated and whether T cell autoreactivity drives local inflammation. Kidney-infiltrating T cells are also observed in urine, where they have high resemblance to interstitial T cells. Therefore, urinary T cells are a proxy for investigating tissue pathogenesis. Here, we analyzed urinary T cells to elucidate whether a kidney-specific T cell autoimmune reaction contributes to tubulointerstitial inflammation in LN. Using single-cell RNA sequencing, we compared transcriptomes and clonotypes of T cells from the blood and urine of patients with active LN and showed that urinary T cells were mostly activated CD8 effector memory cells recruited from a circulating CX3CR1 + subset. Several urinary CD8 T cell clones were expanded. However, upon in vitro testing of their T cell receptors, we did not observe autoreactivity against autologous tubular epithelial cells. Instead, ~20% of expanded clonotypes were Epstein-Barr virus–specific or cytomegalovirus-specific, but respective viral antigens were undetectable in kidney biopsies or urine. Conversely, kidney-infiltrating T cells had access to interleukin-15 and interferon-β (IFN-β), and stimulation with these cytokines was sufficient to trigger degranulation and production of tumor necrosis factor, IFN-γ, and granzyme K. Together, these results show that CD8 + CX3CR1 + T cells are recruited into the kidney in LN, where they are activated by cytokines, enabling them to contribute to local inflammation.


  • Open Access

    Standardizing physical function across assessment types: Three versions of the physical performance test were linked to the PROMIS physical function metric in diverse populations

    by Audrey Yuki Brinker, Frank Buttgereit, Andreas Heißel, Volker Köllner, Ursula Müller-Werdan, Steven Bindseil, Lisa M. Reinhold, Julia Winkler, Volkan Aykac, Udo Schneider, et al.


  • Open Access

    Bridging patient-reported outcomes and performance assessments in older adults: linking the Short Physical Performance Battery to the standardised PROMIS Physical Function scale

    by Gregor Liegl, Audrey Yuki Brinker, Ursula Müller-Werdan, Andreas Heissel, Frank Buttgereit, Volker Köllner, Volkan Aykac, Udo Schneider, Felix H Fischer, Matthias Rose

    Background: Assessment of physical function, a key outcome in geriatric research, relies on either patient-reported or performance-based assessments. While several patient-reported instruments have been successfully linked to the standardised Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function scale, commonly used performance-based tools, such as the Short Physical Performance Battery (SPPB), remain uncalibrated to this scale. This lack of standardisation limits interpretability, comparability, and integration of physical function data across instruments, studies, and clinical settings. Objective: To link SPPB scores to the PROMIS Physical Function T-score metric in older adults. Methods: This analysis is part of the Standardizing-PF project, a prospectively designed cross-sectional study examining the possibility of mapping patient-reported and performance-based assessments onto a common scale. In the present study, 556 older adults (mean age 74 years) from different clinical and community-based settings subsequently completed a generic 20-item PROMIS Physical Function short form (PROMIS-PF20a) and the SPPB. Assumptions of item response theory modelling were investigated. We estimated a unidimensional item response theory-based linking model and derived cross-walks to convert SPPB scores into standardised PROMIS PF T-scores. Results: SPPB and PROMIS-PF20a were highly correlated (latent correlation = 0.89); assumptions of item response theory modelling were fulfilled. After linking, agreement between observed and linked T-scores was stable across several subsamples. Conclusions: The SPPB can be meaningfully linked to the PROMIS PF T-score metric, enabling standardised interpretation, comparison, and aggregation of performance-based and self-reported physical function in older adults. We provide a user-friendly score cross-walk table to facilitate application in clinical practise and standardisation in geriatric research.


  • Seltene Systemerkrankungen

    by Christoph Schäfer, Bimba Franziska Hoyer, Udo Schneider, Janine Günther, Norbert Blank

  • Open Access

    Systemic sclerosis triggered by bleomycin: a 5-year follow-up

    by Philipp Dittert, Martin Krusche, Lennard Ostendorf, Gerhard Krönke, Udo Schneider, Robert Biesen

  • Identification of a distinctive gene signature associated with disease activity in granulomatous myositis

    by Iago Pinal-Fernandez, Nikolas Ruffer, Maria Casal-Dominguez, Katherine Pak, Felix Kleefeld, Corinna Preusse, Raphael A Kirou, Travis B Kinder, Stefania Del Orso, Faiza Naz, et al.

    Objectives: Granulomatous myositis (GM) is defined by focal collections of activated macrophages that fuse to form multinucleated cells that aggregate into granulomas within skeletal muscle. This study aimed to elucidate the pathophysiology of GM by defining its specific transcriptomic profile. Methods: Bulk RNA sequencing was performed on 722 muscle biopsies, including 38 from patients with GM, other myopathies and healthy comparators. Spatial transcriptomics and immunohistochemistry assays were used to identify the location of specific transcripts and proteins within the tissue. Results: We conducted a systematic analysis of the inflammatory pathways implicated in GM. This analysis revealed that GM muscle biopsies are characterized by elevated levels of IFNγ, IFNγ-inducible genes and proinflammatory cytokine genes including IL1B, TNF and TGFB1. Additionally, we identified a specific gene signature in GM, comprising 1293 genes that were significantly upregulated and 256 significantly downregulated. These genes were strongly correlated with transcriptomic markers of disease activity. Using this gene signature, support vector machine models accurately identified GM, achieving an area under the curve of 99.6% (99.0–99.9%) and an accuracy of 98.6% (98.2–98.9%). Among the identified genes, CHIT1 emerged as the most significantly upregulated gene, with its expression strongly correlating with disease severity. Furthermore, CHIT1 was detected at both the RNA and protein levels in granulomas and giant cells. Conclusion: GM is transcriptomically characterized by a strong IFNγ signature and overexpression of proinflammatory cytokines, including IL1B, TNF and TGFB1. Additionally, it exhibits a unique transcriptomic profile, including CHIT1, which correlates with disease activity.


  • Open Access

    Correspondence to: Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome

    by Marie‐Therese Holzer, Robert Biesen, Sarah Tansley, Carsten Dittmayer, Werner Stenzel, Udo Schneider

  • Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A Cross-Sectional Study

    by Andriko Palmowski, Gabriela Schmajuk, Jinoos Yazdany, Patricia Katz, Jing Li, Rachael Stovall, Emma Kersey, Sabrina M. Nielsen, Robin Christensen, Henning Bliddal, et al.